martedì, 24 novembre 2020
Medinews
2 Marzo 2018

Bosutinib Nears EU Approval for Frontline Ph+ CML

February 26, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), according to Pfizer, the developer of the third-generation tyrosine kinase inhibitor. The CHMP recommendation is based on data from the phase III open-label BFORE trial, in which the major … (leggi tutto)

TORNA INDIETRO